Our Take
A unanimous AdCom vote does not guarantee FDA approval, but it substantially de-risks Moderna's vaccine franchise after a February rejection that shocked the sector.
Why it matters
Moderna's vaccine program faced political headwinds and regulatory setbacks under the Trump administration. This approval pathway signals the FDA remains willing to evaluate mRNA-based products on clinical merit, not ideology. Investors and rival vaccine makers are watching closely.
Do this week
Vaccine developers: map Moderna's resubmission playbook (study design, manufacturing, comparative efficacy framing) before your next FDA meeting so you can avoid February's rejection letter.
FDA advisory panel endorses Moderna's mRNA flu vaccine
Moderna's mRNA-1010 (mFlusiva) cleared the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 18, 2025, with a unanimous 9-0 vote in favor of approval for two age groups: adults 50-64 and adults 65 and older. The panel determined that benefits outweigh risks for both populations.
The vaccine demonstrated 26.6% higher relative effectiveness compared to a licensed standard-dose seasonal influenza vaccine in its pivotal Phase III trial (per Moderna's June 2025 trial data). The FDA now has until August 5, 2026 to issue a final decision under the Prescription Drug User Fee Act timeline.
Moderna shares rose 3.5% to $63.96 at market open following the vote, up from a $61.80 close the prior trading day. Citi analysts characterized the unanimous vote as a "clear positive and meaningful de-risking event" heading into the formal FDA review.
Regulatory reversal after high-profile rejection
This AdCom victory marks a sharp turnaround from February 2025, when the FDA refused to accept Moderna's initial application, citing lack of a properly conducted study. That refusal was the most visible regulatory setback for an mRNA vaccine since the modality became politically contested under the Trump administration.
The February rejection occurred despite Moderna's mRNA-1010 using the same underlying technology as Spikevax, its FDA-approved Covid-19 vaccine. In August 2024, the administration cut $500 million in mRNA research funding through BARDA, affecting roughly 22 projects and creating broader sector uncertainty.
The unanimous AdCom recommendation suggests the FDA's review team may be willing to separate clinical evidence from political pressure. However, the panel's recommendation does not bind the agency: the FDA can and occasionally does reject AdCom findings.
William Blair analysts noted that the mRNA-1010 vote should have positive read-through to Moderna's dual flu/Covid vaccine (mCombriax), which combines components from both shots. Moderna voluntarily withdrew that application in May 2025 after FDA consultation. Analysts remain cautious on Moderna's overall vaccine growth trajectory given recent regulatory headwinds.
What this means for vaccine developers and manufacturers
Watch Moderna's resubmission strategy. The company moved from outright rejection to unanimous approval by restructuring its study design and manufacturing approach. Details on what changed between the February submission and the successful resubmission are not yet public, but will become available in FDA briefing documents closer to the August decision date.
If the FDA approves mRNA-1010 on August 5, it resets expectations for other mRNA vaccine candidates in development and signals the agency will evaluate the modality on efficacy data rather than political headwinds. If the FDA departs from the AdCom recommendation, it will create immediate uncertainty across the sector and may prompt other developers to delay submissions pending clarity on FDA standards.
The mCombriax situation is worth tracking. Moderna's voluntary withdrawal suggests the company expects the dual-indication shot faces steeper review questions than a single-indication flu vaccine. Any future resubmission of that product will test whether the FDA views combination mRNA shots as a harder approval problem than standalone candidates.